ResMed, RMD, a leader in cloud-connected medical devices and out-of-hospital software-as-a-service, SaaS, business solutions, today announced it has completed its acquisition of Propeller Health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease, COPD. and asthma.
Propeller will continue to operate as a standalone business out of its Madison, Wisc., and San Francisco offices, working with leading pharmaceutical partners and other healthcare organisations to provide digital therapeutics and actionable insights to people who use inhalers, helping improve their medication adherence, increase their number of symptom-free days, and reduce emergency room visits.
“I’m excited to welcome Propeller, a fellow digital health innovator and high-performing company, into the ResMed family,” Mick Farrell, the ResMed CEO, said. “Propeller’s digital solutions and partnerships strengthen ResMed’s larger suite of products that can treat millions of people at various stages of their COPD and other chronic diseases, all aimed at improving people’s quality of life, while reducing the effects of these diseases, hospitalizations, and the overall cost of healthcare.”
Propeller will operate within ResMed’s Respiratory Care portfolio; Propeller CEO David Van Sickle remains in his role, reporting to ResMed Respiratory Care President Richie McHale.
As ResMed first reported on December 3, 2018, the addition of Propeller’s business is expected to have a dilutive impact on ResMed’s non-GAAP earnings per share in the range of $0.01 to $0.02 per quarter during the remainder of Fiscal Year 2019.
– Jan. 11, 2019 @ 12:45 GMT |